Transtoxbio
Transcell has pioneered an innovative and revolutionary animal-free testing strategy (patent protected) to implement as Digital Animal Replacement Technology (DART) – An Enterprise Solution. This technology is designed to be easily adopted by global bio/pharma companies at various stages of their discovery and development functions. It aligns with the recent FDA Modernization Act 2.0 and the international ban on testing cosmetics on animals, encouraging the use of non-animal cruelty-free testing platforms
- The use of AI/ML-powered digital workstations with prediction models to automate safety or efficacy tests
- Stem cell-based MicroPhysiological in vitro systems that produce human-relevant readouts as clinical surrogate data points when treated with test agents
- Integration into the end-user’s existing workflows to support discovery, development, and manufacturing processes
- Benefits such as phasing out animal testing protocols and building a brand as an ethical organization
- Alignment with the 3Rs in animal testing (Replace, Reduce, Refine)
- Assays offered as modules under a single Application Programming Interface
- Screening – Phenotype Based – Libraries/Hits
- Screening – Lead molecules
- Potency Assessments
- Safety Pharmacology Testings
- Immunogenicity-Antigenicity Assessment
- Biologics Testings
- Ex vivo Clinical Trials
- Product Potency Measurement
- In vitro Pharmacology Assays in Drug Development
Backed by Transcell’s breakthrough scientific innovation in animal-free testing strategy, Quantiphi, with strategic partnerships with technology leaders such as Google Cloud, Amazon Web Services, and NVIDIA, combined with its commitment to HIPAA compliance and ethical AI solutions, ensures that its practices are cutting-edge and compliant with industry standards.
DART Supports Authentic Drug & Vaccine Makers
27-Jan-2025
California’s Afecta Pharmaceuticals officially onboards DART for drug development
2024
Transcell’s scientific leadership confronts the challenges inherent in first-in-human trials and confidently introduces DART: Preparing for First-in-Human Trials – A Strategic Intervention
14-August-2024
Quantiphi Excited to team up with @TranscellBio to revolutionize AI-driven drug discovery!
13-August-2024
Quantiphi Strengthens AI Drug Discovery, Development Collaboration with Transcell Through Strategic Minority Investment
August
Transcell Biologics Private Limited through a strategic investment that’s set to shake up the world of AI-driven drug discovery
16-August-2023
Hetero Biopharma deploys Transcell-Quantiphi’s digital animal replacement technology for drug development
2023
Animal-Free Testing Strategy for Potency Assessment As Critical Quality Attribute – Digital Potency Testing – Invaluable Strategy To Support Antisera Industry
21-April-2022
Transcell Oncologics, ViNS Bioproducts ink MoU for potency testing of anti-venoms
26-August-2022
A revolutionary approach to predict human safety in immunisation programmes involving human stem cells
21-April-2022
Transcell’s scientific leadership discusses new engagement models with the pharmaceutical and biopharmaceutical industry: New Approach Methodologies Concept – Creating a New World Order
11-March-2025
Transcell Biologics has officially joined forces with Pro Anima, a dedicated scientific committee of scientists, academics, medical professionals, and passionate volunteers who advocate for programs that do not involve animal testing. DVES 2025 Prize - The unique French prize dedicated to non-animal research
11-April-2025
Reimagining Drug & Vaccine Testing: The Feasibility of Animal-Free Platforms with Artificial Intelligence
